The future of bladder research: Molecular profiling, new drug targets, gene therapy, and tissue engineering

Current Urology Reports

Volumn 8, Issue 2, 2007, Pages 95-99

  Christ, George ^a   Andersson, Karl Erik ^b   Atala, Anthony ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; COMPLEMENTARY DNA; HERBACEOUS AGENT; ION CHANNEL; LIPOSOME; MANGANESE SUPEROXIDE DISMUTASE; MUSCARINIC M3 RECEPTOR; NERVE GROWTH FACTOR; PREPROENKEPHALIN; PROOPIOMELANOCORTIN; STEROID 5ALPHA REDUCTASE INHIBITOR; DRUG;

BLADDER DYSFUNCTION; CELL TRANSPLANTATION; CYSTITIS; DRUG MECHANISM; DRUG TARGETING; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSCRIPTION; HUMAN; IMPOTENCE; MEDICAL RESEARCH; MICROARRAY ANALYSIS; NOTE; PLASMID; TISSUE ENGINEERING; BLADDER DISEASE; DRUG DELIVERY SYSTEM; FEMALE; FORECASTING; MALE; METHODOLOGY; MOLECULAR BIOLOGY; RESEARCH; REVIEW; STANDARD; TREATMENT OUTCOME;

DRUG DELIVERY SYSTEMS; FEMALE; FORECASTING; GENE THERAPY; HUMANS; MALE; MOLECULAR BIOLOGY; PHARMACEUTICAL PREPARATIONS; RESEARCH; TISSUE ENGINEERING; TREATMENT OUTCOME; URINARY BLADDER DISEASES;

EID: 33847698258     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-007-0056-y     Document Type: Note

References (27)

1. Andersson KE, Appell R, Awad S, et al.: Pharmacological Treatment of Urinary Incontinence. In Incontinence, 3rd International Consultation on Incontinence. Edited by Abrams P, Kbhoury S, Wein A. Paris: Health Publications Ltd; 2005:811-854.
2. Atala A: Recent applications of regenerative medicine to urologic structures and related tissues. Curr Opin Urol 2006, 16:305-309.
3. Atala A, Bauer SB, Soker S, et al.: Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet 2006, 367:1241-1246.
4. Andersson KE, Wein AJ: Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev 2004, 56:581-631.
5. Christ GJ, Hodges SJ, Melman A: An update on gene therapy/transfer treatments for bladder dysfunction. Curr Blad Dys Rep 2007, 1:119-125.
6. Atala A, Koh C: Applications of tissue engineering in the genitourinary tract. Expert Rev Med Devices 2005, 2:119-126.
7. Korossis S, Bolland F, Ingham E, et al.: Review: tissue engineering of the urinary bladder: considering structure-function relationships and the role of mechanotransduction. Tissue Eng 2006, 12:635-644.
8. Hipp JD, Davies KP, Tar M, et al.: Using GeneChips to identify organ-specific, smooth muscle responses to experimental diabetes: Potential applications to urologic diseases. BJU Int 2006, In press.
9. Abdel-Aziz KF, Lemack GE: Overactive bladder in the male patient: bladder, outlet, or both? Curr Urol Rep 2002, 3:445-451.
10. Chapple CR, Roehrborn CG: A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006, 49:651-659.
11. Siroky MB: Lower urinary tract symptoms: shifting our focus from the prostate to the bladder. J Urol 2004, 172:1237-1238.
12. Uckert S, Hedlund P, Andersson KE, et al.: Update on phosphodiesterase (pde) isoenzymes as pharmacologic targets in urology:Present and Future. Eur Urol 2006, In press.
13. Peters SL, Schmidt M, Michel MC: Rho kinase: a target for treating urinary bladder dysfunction? Trends Pharmacol Sci 2006, 27:492-497.
14. Avelino A, Cruz F: TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn Schmiedebergs Arch Pharmacol 2006, 373:287-299.
15. Ford AP, Gever JR, Nunn PA, et al.: Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br J Pharmacol 2006, 147(Suppl 2):S132-S143.
16. Ruggieri MR Sr: Mechanisms of disease: role of purinergic signaling in the pathophysiology of bladder dysfunction. Nat Clin Pract Urol 2006, 3:206-215.
17. Andersson KE, Pehrson R: CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention. Drugs 2003, 63:2595-2611.
18. Bangma CH, Mongiat P, Kraaij R, Schenk-Braat E: Gene therapy in urology: strategies to translate theory into practice. BJU Int 2005, 96:1163-1170.
19. Chancellor MB, Yoshimura N, Pruchnic R, Huard J: Gene therapy strategies for urological dysfunction. Trends Mol Med 2001, 7:301-306.
20. Huard J, Yokoyama T, Pruchnic R, et al.: Muscle-derived cell-mediated ex vivo gene therapy for urological dysfunction. Gene Ther 2002, 9:1617-1626.
21. Lu SH, Cannon TW, Chermanski C, et al.: Muscle-derived stem cells seeded into acellular scaffolds develop calcium-dependent contractile activity that is modulated by nicotinic receptors. Urology 2003, 61:1285-1291.
22. Otani M, Yoshida M, Iwashita H, et al.: Electroporation-mediated muscarinic M3 receptor gene transfer into rat urinary bladder. Int J Urol 2004, 11:1001-1008.
23. Sasaki K, Chancellor MB, Goins WF, et al.: Gene therapy using replication-defective herpes simplex virus vectors expressing nerve growth factor in a rat model of diabetic cystopathy. Diabetes 2004, 53:2723-2730.
24. Chuang YC, Chou AK, Wu PC, et al.: Gene therapy for bladder pain with gene gun particle encoding pro-opiomelanocortin cDNA. J Urol 2003, 170:2044-2048.
25. Goins WF, Yoshimura N, Phelan MW, et al.: Herpes simplex virus mediated nerve growth factor expression in bladder and afferent neurons: potential treatment for diabetic bladder dysfunction. J Urol 2001, 165:1748-1754.
26. Kanai AJ, Zeidel ML, Lavelle JP, et al.: Manganese superoxide dismutase gene therapy protects against irradiation-induced cystitis. Am J Physiol Renal Physiol 2002, 283:F1304-F1312.
27. Christ GJ, Day NS, Day M, et al.: Bladder injection of "naked" hSlo/pcDNA3 ameliorates detrusor hyperactivity in obstructed rats in vivo. Am J Physiol Regul Integr Comp Physiol 2001, 281:R1699-R1709.